Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study

Background. The treatment options for patients with multiple myeloma who refractory to previous bortezomib and lenalidomide therapy are limited. Pomalidomide is ап immunomodulatory agent that was registered for the treatment of patients with double refractory multiple myeloma.

Aim. To evaluate efficacy, safety and optimal course of the therapy with pomalidomide in routine practice in patients with double refractory multiple myeloma.

Materials and methods. Overall, 71 patients with double refractory multiple myeloma were included in the retrospective analysis. There were 36 males and 35 females. The median age was 61 years (range 35-79). According to Durie-Salmon staging system, there were 53 (79.1 %) patients in stage III, 13 (19.4 %) - stage II, and 1 (1.5 %) - stage I.

The stage was unknown in 4 patients. Kidney impairment at the onset was in 10 (15 %) patients, the normal function was in 57 (85 %) patients and 4 patients had no data. Most patients (n = 68, 95.8 %) received pomalidomide in one therapy line, in 3 (4.2 %) patients - drug was given in two lines, totally 74 episodes of use. Median number of drugs prescribed prior to pomalidomide were 4 (2-9) drugs, including target ones - 2 (2-5). In the first remission 31 (43.6 %) patients received high-dose therapy with autologous stem cell transplantation. pomalidomide was administered in combination with low doses of dexamethasone (PomDex, n = 44; 59.4 %) and as a part of triple regimens (n = 30; 40.6 %). previously exposed (n = 22; 73.3 %) and new drugs (n = 8; 26.7 %) were used in the combination treatment. In 44 (61.9 %) patients pomalidomide was administered more than 3 years after the onset of the disease, median 63.5 (37-184) months. In 27 (38.1 %) patients it was given within less than 3 years after the onset, median 21 (6-36) months. The primary endpoint was progression-free survival. Secondary endpoints - pomalidomide tolerability, response rate and optimal third drug in the triple regimen. The dependence of progression-free survival, frequency of response and adverse events from the pretreatment, the choice of the third drug, gender, age, immunochemical variant, stage according to the International Staging System and to Durie-Salmon classification was studied.

Results. The median time from the diagnosis to the start of pomalidomide therapy was 44.5 (6-184) months. The median of cycles with pomalidomide was 3 (1-30). The response was achieved in 52 (70 %) patients. The median progression-free survival was 4 (1-30) months, overall survival - 6 (0.5-42) months. Adverse effects were noted in 34 (46.5 %) patients. The most frequent adverse events were neutropenia grade III-IV (n = 14; 41.3 %), infection (n = 7; 20.7 %) and fatigue with limitation of daily activity (n = 6; 20.6 %). The rate of adverse events was higher in patients with triplets than doublets regimens of therapy: 43.3 % (n = 13) and 27.2 % (n = 12) respectively (p = 0.008). There were no statistically significant differences in progression-free survival between pomalidomide treatment options (two- or three-component regimen).

Conclusion. Compared to the three-component therapy consisting of drugs to which refractoriness was previously diagnosed the PomDex scheme is less toxic and equally effective. Therapy with pomalidomide is effective in the majority of patients with double refractory multiple myeloma even in heavily pretreated. The toxicity is acceptable.

1. SEER stat fact sheets: myeloma. National Institutes of Health, National Cancer Institute Surveillance, Epidemiology, and End Results Program. Available at: http://seer.cancer.gov/statfacts/html/mulmy.html (accessed January 16, 2016).

2. Malignant tumors in Russia in 2017 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMITS radiologii” Minzdrava Rossii, 2018. 250 p. (In Russ.).

3. Luchinin A.S., Semochkin S.V., Minaeva N.V. et al. Epidemiology of multiple myeloma according to the Kirov region population registers. Onkogematologiya = Oncohematology 2017;12(3):50-6. (In Russ.). DOI: 10.17650/1818-83462017-12-3-50-56

4. Kyle R.A., Steensma D.P. History of multiple myeloma. Recent Results Cancer Res 2011;183:3-23. DOI: 10.1007/978-3-540-85772-3_1

5. Blokhin N., Larionov L., Perevodchi-kova N. et al. Clinical experiences with sarcolysin in neoplastic diseases. Ann N Y Acad Sci 1958;68(3):1128-32.

6. Stem cells - from bone marrow transplantation to cell therapy. B.V. Afanasiev Commencement Address dedicated to the 115th anniversary of the I.P. Pavlov First Saint-Petersburg State Medical University (20.12.2012). (In Russ.).

7. Moreau P., San Miguel J., Sonneveld P. et al. ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(Suppl 4):iv52-61. DOI: 10.1093/annonc/mdx096

8. Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases. Under the guidance of I.V. Poddubnaya, V.G. Savchenko. Moscow: Buki Vedi, 2018. 324 р. (In Russ.).

9. Kumar S.K., Lee J.H., Lahuerta J.J. et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012;26(1):149-57. DOI: 10.1038/leu.2011

10. Potapenko V.G., Kotova N.A., Zabuto-va Yu.V. et al. The incidence of bortezomib and lenalidomide resistance in patients with multiple myeloma. Single center experience. Abstracts of the XIV Symposium in memory of R.M. Gorbacheva “Transplantation of hematopoietic stem cells. Gene and Cell Therapy”. Kletochnaya terapiya i transplantatsiya = Cellular Therapy and Transplantation 2021;10(3):35-6. (In Russ.).

11. Ocio E.M., Fernandez-Lazaro D., San-Segundo L. et al. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia 2015;29(3):705-14. DOI: 10.1038/leu.2014.238

12. Quach H., Ritchie D., Stewart A.K. et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24(1):22-32. DOI: 10.1038/leu.2009.236

13. Richardson P.G., Siegel D., Baz R. et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 2013;121(11):1961-7. DOI: 10.1182/blood-2012-08-450742

14. Decaux O., Macro M., Gourgou S. et al. Four-year interim analysis of Miroir, a French multicenter, non-interventional study of pomalidomide in relapsed/ refractory multiple myeloma. Blood 2019;134(Suppl 1):1836. DOI: 10.1182/blood-2019-124484

15. Miguel J.S., Weisel K., Moreau P. et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14(11):1055-66. DOI: 10.1016/S1470-2045(13)70380-2

16. Petrov A.V., Motorin D.V., Pokrovskaya O.S. et al. Pomalidomide in combination with low-dose dexamethasone as the treatment of “double refractory” multiple myeloma. Klinicheskaya onkogematologiya = Clinical Oncohematology 2017;10(3):372-80. (In Russ.). DOI: 10.21320/2500-21392017-10-3-372-380

17. Dimopoulos M., Bringhen S., Anttila P. et al. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. Blood 2021;137(9):1154-65. DOI: 10.1182/blood.2020008209

18. Gross Z., Rahbari A., Wirtschafter E. et al. Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: a retrospective study. Eur J Haematol 2018;100(6):621-3. DOI: 10.1111/ejh.13058

19. Ailawadhi S., Sexton R., Lentzsch S. et al. Low-dose versus high-dose carfilzomib with dexamethasone (S1304) in patients with relapsed-refractory multiple myeloma. Clin Cancer Res 2020;26(15):3969-78. DOI: 10.1158/1078-0432.CCR-19-1997

20. Lonial S., Weiss B.M., Usmani S.Z. et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016;387(10027):1551-60. DOI: 10.1016/S0140-6736(15)01120-4

21. Attal M., Richardson P.G., Rajkumar S.V. et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. ICARIA-MM study group. Lancet 2019;394(10214):2096-107. DOI: 10.1016/S0140-6736(19)32556-5

22. Dimopoulos M.A., Palumbo A., Corradini P. et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood 2016;128(4):497-503. DOI: 10.1182/blood-2016-02-700872

23. Dimopoulos M.A., Dytfeld D., Grosicki S. et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. Engl J Med 2018;379(19):1811-22. DOI: 10.1056/NEJMoa1805762

24. Larocca A., Montefusco V., Bringhen S. et al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood 2013;122(16):2799-806. DOI: 10.1182/blood-2013-03-488676

25. Lee H.S., Kim K., Kim S.J. et al. Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMMWP-164 study). Am J Hematol 2020;95(4):413-21. DOI: 10.1002/ajh.25726

26. Swerdlow S., Campo E., Harris N. et al. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th revise. Lyon, France: IARC Press, 2017.

27. Kumar S., Paiva B., Anderson K. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17(8):e328-46. DOI: 10.1016/S1470-2045(16)30206-6

28. Baz R.C., Martin T.G.3rd, Lin H.Y. et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood 2016;127(21):2561-8. DOI: 10.1182/blood-2015-11-682518

29. Nooka A.K., Joseph N.S., Kaufman J.L. et al. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: utility of re-treatment with daratumumab among refractory patients. Cancer 2019;125(17):2991-3000. DOI: 10.1002/cncr.32178

30. Pomalidomide Instructions for use. (In Russ.).

31. Lacy M.Q., Hayman S.R., Gertz M.A. et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009;27(30):5008-14. DOI: 10.1200/JCO.2009.23.6802

32. Lacy M.Q., Allred J.B., Gertz M.A. et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dualrefractory disease. Blood 2011;118(11):2970-5. DOI: 10.1182/blood-2011-04-348896

33. Porunova V.V. Therapy results of multiple myeloma patients with bone and/or extramedullary plasmacytomas. Gematologiya i transfuziologiya = Hematology and Transfusiology 2020;65(Suppl 1):204. (In Russ.).

34. Short K.D., Rajkumar S.V., Larson D. et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 2011;25(6):906-8. DOI: 10.1038/leu.2011.29

35. Jimenez-Segura R., Granell M., Gironella M. et al. Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed/ refractory multiple myeloma. Eur J Haematol 2019;102(5):389-94. DOI: 10.1111/ejh.13217

36. Soekojo C.Y., Kim K., Huang S.Y. et al. Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001) - a trial by the Asian Myeloma Network. Blood Cancer J 2019;9(10):83. DOI: 10.1038/s41408-019-0245-1

37. Dimopoulos M., Weisel K., Moreau P. et al. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia 2021;35(6):1722-31. DOI: 10.1038/s41375-020-01021-3

38. Poddubnaya I.V., Tumyan G.S., Trofimova O.P. et al. Features of management of oncohematological patients in the context of the COVID-19 pandemic. Sovremennaya onkologiya = Journal of Modern Oncology 2020;22(3):45-58. (In Russ.). DOI: 10.26442/18151434.2020.3.200152

39. Terpos E., Engelhardt M., Cook G. et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia 2020;34(8):2000-11. DOI: 10.1038/s41375-020-0876-z

40. Malard F., Mohty M. Management of patients with multiple myeloma during the COVID-19 pandemic. Lancet Haematol 2020;7(6):e435-7. DOI: 10.1016/S2352-3026(20)30124-1